摘要
目的:检测大肠癌患者术中应用化疗药物后,手术前后血清CEA和CA19-9的变化,确定其对预防大肠癌微转移,降低术后复发率和死亡率的临床意义.方法:采用ELISA方法测定30例术中应用化疗药物大肠癌患者及30例术中未应用化疗药物大肠癌患者手术前后外周血中CEA和CA19-9含量的变化,同时选用30例非肿瘤人群作为正常对照.结果:60例大肠癌患者(DuckC期)术前外周血中CEA,CA19-9均值高于正常值(60.73±25.99mg/Lvs2.67±1.643mg/L,P<0.01;112.73±78.76kU/Lvs14.6±6.68kU/L,P<0.01).30例术中应用化疗药物的大肠癌患者手术后血清CEA、CA19-9下降较快(术后7d:7.96±3.32mg/L,29.34±11.05kU/L,P<0.01vs术前),术中未应用化疗药物组的大肠癌患者术后血清CEA和CA-199下降缓慢(术后7d:34.23±20.59mg/L,88.12±32.28kU/L,P>0.05vs术前).结论:通过定量检测大肠癌患者外周血CEA和CA19-9的含量,证明手术中温热灌注化疗+动脉化疗以及术后联合化疗的辅助治疗是十分必要的,对预防大肠癌微转移,降低术后复发率和死亡率的有重要的临床意义.
AIM： To observe the pre- and post-operational changes of serum carcinoembryonic antigen （CEA） and carbohydrate antigen 19-9 （CA19-9） in patients with progressive colon cancer and their clinical significances.
METHODS： The serum levels of CEA and CA19-9 were detected by indirect enzyme-linked immunosorbent assay （ELISA） in 60 patients （30 cases received chemotherapy during operation while 30 cases did not） diagnosed with colon cancer and 30 normal volunteers.
RESULTS： The serum levels of CEA and CA19-9 were significantly higher in all the cancer patients before operation than those in the normal controls （60.73 ± 25.99 mg/L vs 2.67 ± 1.643 mg/L, P 〈 0.01; 112.73 ± 78.76 kU/L vs 14.6 ± 6.68 kU/L,P 〈 0.01）. CEA and CA19-9 levels were rapidly decreased in the patients received chemotherapy （7 d post-operation： 7.96 ± 3.32 mg/L, 29.34 ± 11.05 kU/L, P 〈 0.01 vs pre-operation）, but they were not significantly decreased in the patients without chemotherapy （7 d： post-operation： 34.23 ± 20.59 mg/L, 88.12 ± 32.28 kU/L, P 〉 0.05 vs pre-operation）.
CONCLUSION： Detection of CEA and CA19-9 in the peripheral blood confirms that portal vein continuous chemotherapy and great volume of intraperitoneal chemotherapy are effective in preventing postoperative metastasis of colorectal cancer.
出处
《世界华人消化杂志》
CAS
北大核心
2007年第1期82-85,共4页
World Chinese Journal of Digestology
关键词
大肠癌
术中化疗
癌胚抗原
糖类抗原19-9
Colorectal cancer
Intraperitoneal chemotherapy
Carcinoembryonic antigen
Carbohydrate antigen 19-9
